Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRBP vs IMMX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–0 Matrix Metrics)

IMMX Overall Winner 6-Pillar Tally: CRBP 1 – 3 IMMX (2 Tie) Matrix Metrics: CRBP 0 – 6 IMMX

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas IMMX carries 50.3/100 (HOLD) at $7.48 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRBP vs IMMX
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 121% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.8%), weak momentum, RSI 34
RSI-14: 34.3 · SMA20: $3.83 · SMA50: $5.51
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.48
-4.59% 1D
Market Cap $657.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.80β · 84% Vol
Unified Composite Score
50.3 / 100 HOLD
Tech 52.0 Fund 55.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $8.05 · SMA50: $9.69

6-Pillar Scorecard Institutional Category Breakdown (CRBP 1 – 3 IMMX)

Columns: Metric · CRBP · IMMX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale IMMX
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $69.9M $657.1M
3. Profitability & Quality IMMX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -131.5% -27.0%
4. Balance Sheet & Cash Flow CRBP
Cash Generation (TTM) -$92M -$39M
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $224M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMMX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 197.6% (66th %ile) 92.6% (17th %ile)
Put/Call OI Skew N/A 1.24x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRBP (0) vs IMMX (6)
Institutional Metric CRBP IMMX Criterion Row Edge
Market Capitalization
Scale
$69.9M $657.1M Larger Scale IMMX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth IMMX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-131.5% -27.0% Higher ROE IMMX
52-Week Range Position
Momentum
6% ($3–$13) 35% ($3–$15) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
1.93β · 121% Vol 1.80β · 84% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 50.3 / 100 (HOLD) Higher Composite IMMX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$92M ($26M Net Cash) -$39M ($224M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMMX +19.06 pp
CRBP: -25.33% · IMMX: -6.27%
3M Horizon IMMX +29.86 pp
CRBP: -66.52% · IMMX: -36.66%
6M Horizon IMMX +49.28 pp
CRBP: -66.08% · IMMX: -16.8%
1Y Horizon IMMX +176.71 pp
CRBP: -69.51% · IMMX: +107.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRBP vs IMMX. Trailing 12-month operating profitability (CRBP 0.0% vs IMMX 0.0%) and valuation multiples (CRBP N/M vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-131.5% · N/M
IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRBP BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 197.6%
IV Percentile 66th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMX BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 92.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.24x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $69.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $657.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRBP vs IMMX Key Questions & Quantitative Answers

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas IMMX carries 50.3/100 (HOLD) at $7.48 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMMX leads the Growth & Scale pillar: CRBP posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRBP generates N/A in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, CRBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.

CRBP and IMMX trade at balanced relative valuation multiples. CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRBP (-131.5% ROE) versus IMMX (-27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk). By comparison, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 84% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.